Research Article

Identification of Circulating Exosomal miR-101 and miR-125b Panel Act as a Potential Biomarker for Hepatocellular Carcinoma

Figure 6

The diagnostic utility of circulating exosomal miR-101 and miR-125b was further validated to be potential biomarkers for HCC. (a) Circulating exosomal miR-101 was downregulated in patients with HCC compared to healthy controls. Data are presented as . . (b) Circulating exosomal miR-125 was downregulated in patients with HCC compared to healthy controls. Data are presented as . . (c) The AUC was 0.894 (95% CI, 0.793–0.994) for miR-101, 0.812 (95% CI, 0.675–0.950) for miR-125b, and 0.953 (95% CI, 0.895–1.000) for the miRNA combination.
(a)
(b)
(c)